Velusetrag - Theravance Biopharma

Drug Profile

Velusetrag - Theravance Biopharma

Alternative Names: TD-5108

Latest Information Update: 01 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theravance
  • Developer Alfa Wassermann SpA; Theravance Biopharma
  • Class Azabicyclo compounds; Gastrokinetics; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastroparesis
  • Discontinued Alzheimer's disease; Constipation

Most Recent Events

  • 01 Feb 2018 Velusetrag is still at phase II development stage for Gastroparesis in USA, Czech Republic and Poland (PO) (Theravance Biopharma pipeline, February 2018)
  • 03 Aug 2017 Adverse events and efficacy data from a phase IIb trial in Gastroparesis released by Theravance
  • 01 Jul 2017 Theravance completes a phase IIb trial for Gastroparesis in USA, Czech republic and Poland (NCT02267525)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top